Nouvex™ technology was discovered at Purdue University. Poly Group LLC has secured an exclusive, worldwide license to the IP covering Nouvex™ technology which includes a granted US patent.
The Nouvex™ technology is positively charged, so it attracts negatively charged pathogens and destroys them on contact without inducing the resistance. Nouvex™ is high-speed. It also has very high efficacy, which makes it competitive with disinfectants as opposed to traditional antimicrobial additives. Nouvex™ is also highly persistent and has high surface endurance because it is integrated directly into the material. Other market competitors are not as valuable because they are applied as a coating that can wipe or wear off over time. This integrated character of Nouvex™ makes it very desirable for medical uses, textiles, plastics and even glass applications. Nouvex™ also gets high biocompatibility ratings and is more biocompatible than other current antimicrobials. Nouvex™ creates no chemical binding or linking issues, unlike other quaternary ammonium compounds and has a large molecular structure providing limited toxicity. Tunable physical properties allow formulas to be tweaked for efficacy and biocompatibility. It can also be soluble or non-soluble in water or solvents, which allows for a great variety of product applications.
On top of everything else, Nouvex™ formulas are easy to synthesize, making it relatively inexpensive to produce. Its manufacturing costs are low. Nouvex™ has proven performance through testing at GLP (Good Lab Practice) Laboratories, so the EPA preservative and health claims will be accessible to the end-use product manufacturers. All this makes Nouvex™ an immediate replacement for silver ions, triclosan, copper, and other quaternary substances with little or no process modification.
The efficacy testing was done on a variety of gram positive and gram negative bacteria, including: Pseudomonas aeruginosa, Salmonella enterica, Staphylococcus aureus (MRSA), Clostridium difficile (C. diff), Enterococcus faecalis (VRE), Klebsiella pneumoniae, Bacillus cereus, and Escherichia coli MS2 bacteriophage.